Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Nature

Volumn 569, Issue 7756, 2019, Pages 428-432

  Perez Ruiz, Elisabeth ^a,b,c,d,e   Minute, Luna ^a,b   Otano, Itziar ^a,b   Alvarez, Maite ^a,b   Ochoa, Maria Carmen ^a,b,f   Belsue, Virginia ^a,b   de Andrea, Carlos ^b,c   Rodriguez Ruiz, Maria Esperanza ^a,c   Perez Gracia, Jose Luis ^b,c,f   Marquez Rodas, Ivan ^f,g   Llacer, Casilda ^h   Alvarez, Martina ^e,i   de Luque, Vanesa ^e,i   Molina, Carmen ^a,b   Teijeira, Alvaro ^a,b,f   Berraondo, Pedro ^a,b,f   Melero, Ignacio ^a,b,c,f  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d HOSPITAL COSTA DEL SOL   (Spain)

^e Institute of Biomedical Research in Malaga and BIONAND Nanomedicine Platform   (Spain)

^f Autonomous University of Madrid Instituto de Investigación Hospital Universitario La Paz   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁱ UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; CTLA4 PROTEIN, HUMAN; DEXTRAN SULFATE; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL TRANSFER; COLITIS; COLON ADENOCARCINOMA; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; GENE; GRAFT VERSUS HOST REACTION; HEPATITIS; HUMAN; HUMAN CELL; IL2RG GENE; LETTER; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAG2 GENE; TUMOR XENOGRAFT; UPREGULATION; ADVERSE EVENT; ANIMAL; C57BL MOUSE; CD8+ T LYMPHOCYTE; COLON TUMOR; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; IMMUNOTHERAPY; T LYMPHOCYTE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; COLITIS; COLONIC NEOPLASMS; CTLA-4 ANTIGEN; DEXTRAN SULFATE; FEMALE; GRAFT VS HOST DISEASE; HEPATITIS; HUMANS; IMMUNOTHERAPY; IPILIMUMAB; MALE; MICE; MICE, INBRED C57BL; NIVOLUMAB; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85065226493     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-019-1162-y     Document Type: Article

References (31)

1. Wolchok, J. D., Rollin, L. & Larkin, J. Nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 2503–2504 (2017).
2. Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
3. Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).
4. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
5. Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275–4280 (2010).
6. Duraiswamy, J., Kaluza, K. M., Freeman, G. J. & Coukos, G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73, 3591–3603 (2013).
7. Wainwright, D. A. et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20, 5290–5301 (2014).
8. + T cells directly within the tumor microenvironment. J. Immunother. Cancer 2, 3 (2014).
9. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
10. Ascierto, P. A. et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 18, 611–622 (2017).
11. Postow, M. A. & Hellmann, M. D. Adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 1163–1165 (2018).
12. Yamada, Y., Kirillova, I., Peschon, J. J. & Fausto, N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc. Natl Acad. Sci. USA 94, 1441–1446 (1997).
13. Cooper, H. S., Murthy, S. N., Shah, R. S. & Sedergran, D. J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69, 238–249 (1993).
14. Eichele, D. D. & Kharbanda, K. K. Dextran sodium sulfate colitis murine model: an indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J. Gastroenterol. 23, 6016–6029 (2017).
15. Blonski, W., Buchner, A. M. & Lichtenstein, G. R. Treatment of ulcerative colitis. Curr. Opin. Gastroenterol. 30, 84–96 (2014).
16. Popivanova, B. K. et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118, 560–570 (2008).
17. Coward, J. et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 17, 6083–6096 (2011).
18. Mace, T. A. et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67, 320–332 (2018).
19. Bertrand, F. et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat. Commun. 8, 2256 (2017).
20. Hettich, M., Braun, F., Bartholomä, M. D., Schirmbeck, R. & Niedermann, G. High-resolution PET Imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics 6, 1629–1640 (2016).
21. + tumor-infiltrating T cells. Immunity 50, 181–194.e6 (2019).
22. + T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211.e10 (2019).
23. Arakaki, R., Yamada, A., Kudo, Y., Hayashi, Y. & Ishimaru, N. Mechanism of activation-induced cell death of T cells and regulation of FasL expression. Crit. Rev. Immunol. 34, 301–314 (2014).
24. Zheng, L. et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348–351 (1995).
25. null immunodeficient mice. Cancer Res. 75, 3466–3478 (2015).
26. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361–371 (2009).
27. Madhusudan, S. et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J. Clin. Oncol. 23, 5950–5959 (2005).
28. Harrison, M. L. et al. Tumor necrosis factor α as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 25, 4542–4549 (2007).
29. Xiao, Y. T., Yan, W. H., Cao, Y., Yan, J. K. & Cai, W. Neutralization of IL-6 and TNF-α ameliorates intestinal permeability in DSS-induced colitis. Cytokine 83, 189–192 (2016).
30. Mähler, M. et al. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am. J. Physiol. 274, G544–G551 (1998).
31. Tang, Q. et al. Role of far upstream element binding protein 1 in colonic epithelial disruption during dextran sulphate sodium-induced murine colitis. Int. J. Clin. Exp. Pathol. 7, 2019–2031 (2014).